A

Amgen

Makes biotech medicines for serious illnesses

Senior Manager, Construction Contractor Safety

Full-TimeUpdated on 10/24/2026
$150.4k - $203.4k+ Discretionary annual bonus + Stock-based long-term incentives
Mid, Senior
Bachelor's, Master's, PhD, Associate's
Thousand Oaks, CA, USA+3 moreMore locations: Holly Springs, NC, USA | New Albany, OH, USA | West Greenwich, RI, USA
In PersonOn site; approximately 50% travel, including regional, domestic, or international travel based on location and business needs.
Facilities OperationsEnvironmental Health & Safety
H1B Sponsorship Available

About the job

Requirements
  • A doctorate degree and 2 years of experience in Environmental Health and Safety, Occupational Safety, Engineering, or a related EHS discipline; or a master's degree and 6 years of such experience; or a bachelor's degree and 8 years of such experience; or an associate's degree and 10 years of such experience; or a high school diploma/GED and 12 years of such experience.
  • At least 2 years of experience directly managing people and/or leadership experience leading teams, projects, programs, or directing the allocation of resources; this may run concurrently with the required technical experience.
  • Demonstrated knowledge and application of safety regulations and construction technical standards, principles, and techniques.
  • Demonstrated ability to solve complex safety problems and develop practical, compliant solutions.
  • Ability to work independently under minimal direction and determine an appropriate approach to assigned responsibilities.
  • Ability to travel approximately 50%, including regional, domestic, or international travel based on role location and business needs.
Responsibilities
  • Lead the development, implementation, and continuous improvement of construction contractor safety program elements, modules, systems, standards, and training.
  • Participate as a member of capital project leadership teams and advise management on project safety performance, priorities, operations, and scheduling considerations.
  • Ensure effective governance processes for tracking safety performance across capital projects through the collection, review, and interpretation of meaningful metrics.
  • Use safety metrics and performance trends to recommend and implement changes that refocus safety efforts and improve outcomes.
  • Identify and implement appropriate technology solutions, including emerging tools such as artificial intelligence, to improve construction safety management efficiency and effectiveness.
  • Monitor contractor and subcontractor compliance with applicable regional safety regulations, construction and general industry safety standards, and company requirements.
  • Manage EHS prequalification and, where applicable, requalification of design and construction contractors and subcontractors by confirming adequate training, knowledge, experience, and resources to meet their EHS obligations.
  • Review contractor project-specific safety plans and verify that appropriate systems and resources are in place to support safe project execution.
  • Ensure contractor and subcontractor orientation and training are provided to impacted personnel, and ensure project engineers and managers receive training on company expectations for construction safety management.
  • Coordinate with appointed project supervisors and other designated safety roles, providing information and cooperation necessary for them to fulfill their health and safety obligations.
  • Manage designated construction safety service-provider or project-supervisor contracts, as applicable to the site or region.
  • Ensure adequate systems and resources are available to review and approve construction activity risk assessments and method statements, including STAs and JHAs, in a timely and compliant manner.
  • Facilitate safety performance reviews, field inspections, and audits, and ensure identified non-conformances are documented, communicated, tracked, and addressed.
  • Monitor and prioritize the safety agenda based on project schedules, project load, risk profile, and emerging conditions.
  • Compile, analyze, and report safety statistics and performance information to management as required.
  • Participate in incident investigations as necessary, and support communication of root cause analysis, corrective actions, and lessons learned.
  • Escalate incidents based on the incident management standard operating procedure.
Desired Qualifications
  • At least 10 years of construction safety experience supporting large capital projects.
  • A bachelor's degree in Environmental Health and Safety, Occupational Safety, Engineering, or a related EHS discipline.
  • Experience managing construction safety in the pharmaceutical or biopharmaceutical industry.
  • Experience supporting contractor safety governance across multiple capital projects, sites, or regions.
  • Experience using technology and data analytics to strengthen construction safety performance.
  • Professional safety certification such as Certified Safety Professional, Certified Industrial Hygienist, or equivalent.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

PR Newswire
Oct 26th, 2026
Amgen appoints former Yum! Brands CEO David Gibbs to its board

Amgen has appointed David W. Gibbs to its board of directors, effective immediately. He will serve on the Audit Committee and the Compensation and Management Development Committee. Gibbs recently retired as president and chief executive officer of Yum! Brands, owner of Taco Bell and Kentucky Fried Chicken. As chief executive from 2020 to 2025, he led its digital transformation and expanded it to nearly 61,000 locations. He has sat on the board of Under Armour since 2021 and PepsiCo since 2026. "His experience creating direct relationships with customers will help inform how we prepare for future launches," said Robert A. Bradway, Amgen's chairman and chief executive officer. The board now has 13 directors, 12 of them independent.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.